Atea Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.53, missing the estimate of USD -0.44.

EBIT: As of FY2025 Q3, the actual value is USD -49.28 M.

Research and Development Expenses: Increased to $38.3 million for the three months ended September 30, 2025, from $26.2 million in the same period in 2024. For the nine months ended September 30, 2025, R&D expenses decreased to $100.2 million from $118.4 million in the same period in 2024.
General and Administrative Expenses: Decreased to $7.2 million for the three months ended September 30, 2025, from $11.0 million in the same period in 2024. For the nine months ended September 30, 2025, G&A expenses decreased to $25.7 million from $35.5 million in the same period in 2024.
Net Loss: Increased to $42.0 million for the three months ended September 30, 2025, from $31.2 million in the same period in 2024. For the nine months ended September 30, 2025, net loss decreased to $113.5 million from $134.8 million in the same period in 2024.

Net Cash Used in Operating Activities: $103.8 million for the nine months ended September 30, 2025, compared to $105.1 million for the same period in 2024.
Net Cash Provided by Investing Activities: $142.2 million for the nine months ended September 30, 2025, compared to $59.5 million for the same period in 2024.
Net Cash Used in Financing Activities: $25.7 million for the nine months ended September 30, 2025, compared to $0.3 million provided by financing activities for the same period in 2024.

Stock Repurchase Program: Completed repurchase of 7,673,792 shares of common stock for an aggregate price of $25.0 million, including transaction costs and excise taxes, as of September 30, 2025.

HCV Phase 3 Clinical Trials: Ongoing Phase 3 clinical trials for bemnifosbuvir and ruzasvir, with patient enrollment in the C-Beyond and C-Forward trials beginning in April and June 2025, respectively.
Financial Resources: Existing financial resources are believed to be sufficient to fund operations through 2027, including the completion of Phase 3 clinical development for HCV treatment.

COVID-19 Program: Discontinued development of bemnifosbuvir for COVID-19 following unfavorable Phase 3 SUNRISE-3 trial results.
HEV and Other RNA Virus Infections: Efforts are ongoing to discover product candidates for HEV and other single-stranded RNA virus infections.

Cost Reduction: Workforce reduction by approximately 25% in the first quarter of 2025, expected to save approximately $15.0 million through 2027.
Strategic Alternatives: Concluded engagement with Evercore LLC but remains open to opportunities to drive stockholder value, including strategic transactions.